Seelos Therapeutics Inc. (NASDAQ:SEEL) does about 1.17M shares in volume on a normal day but saw 5373236 shares change hands in Tuesday trading. The company now has a market cap of 46.54M USD. Its current market price is $0.98, marking an increase of 6.74% compared to the previous close of $0.92. The 52 week high reached by this stock is $1.71 whilst the lowest price level in 52 weeks is $0.42. The script in recent trading has seen the stock touch a high of $1.13 and a low of $0.90.
Seelos Therapeutics Inc. (SEEL) has a 20-day trading average at $1.0586 and the current price is -42.40% off the 52-week high compared with 134.09% distance from its 52-week low. The 50-day simple moving average of the closing price is $1.1029 and its 200-day simple moving average is $0.9711. If we look at the stock’s price movements over the week, volatility stands at 10.99%, which decreases to 8.74% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 42.84 to suggest the stock is neutral.
2 analysts observing the Seelos Therapeutics Inc. (SEEL) stock have set the 12-month price targets for the company’s shares at between $4.00 and $12.00. The median price target is 87.75% away from the current levels at $8.00.
FactSet Research has provided data showing that 2 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 2 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 14, 2019 when The Benchmark Company initiated the stock to “Speculative Buy” and issued a price target of $4.
The current price level is -7.36%, -11.46%, and 1.20% away from its SMA20, SMA50, and SMA200 respectively, with the SEEL price moving above the 50-day SMA on August 25. Seelos Therapeutics Inc. (SEEL) stock is down -2.77% over the week and -5.58% over the past month. Its price is -26.72% year-to-date and -31.81% over the past year.
The company’s next earnings report is expected on 08/25/2020, with forecasts estimating quarterly EPS at $Sealed Air Corporation and $Consumer Cyclical for whole year.
Its 12-month price target is $8.00. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $4.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $12.00.
The company has a return on equity of -431.30%. The beta has a value of 2.16. Price to book ratio is 12.27 and price to sales ratio is 116.34.
According to a U.S. Securities and Exchange Commission filing, FCP Medical – BioHealth has reduced its position in Seelos Therapeutics Inc. (SEEL) to 342,806 shares, mirroring a recent drop by -0.22%. FCP Medical – BioHealth dumped 757.0 shares of Seelos Therapeutics Inc. common stock bringing its total worth to about $0.4 million at the end of recent close, SEC documents show. FCP Medical – BioHealth isn’t the only investment manager who changed stakes and is followed by Vanguard Extended Market Index Fu, which sold off 0.0 shares to end up with 285,349 shares worth $0.33 million. Fidelity Extended Market Index Fu cut their holdings by 0.00% in the company over the course of the most recent quarter. It now holds a 0.20% position in Seelos Therapeutics Inc. thanks to 88253.0 shares amounting to $0.1 million.